![Graham Walmsley](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Graham Walmsley
Direktor/Vorstandsmitglied bei
OLEMA PHARMACEUTICALS, INC.
Vermögen: - $ am 31.08.2026
Profil
Dr. Graham G.
Walmsley is an Independent Director at Olema Pharmaceuticals, Inc., a Managing Partner at Logos Capital Fund LLP, a General Partner at Logos Global Management LP and a Managing Partner at Logos Capital LLC /Ca/.
He is on the Board of Directors at Olema Pharmaceuticals, Inc. and ALX Oncology, Inc. Dr. Walmsley was previously employed as an Independent Director by Lifesci Acquisition II Corp., an Independent Director by ALX Oncology Holdings, Inc., an Independent Director by Akero Therapeutics, Inc., a Head-Business Development by Pipeline Therapeutics, Inc., a Head-Business Development by Jecure Therapeutics, Inc., and a Principal by Versant Venture Management LLC.
He also served on the board at Science 37 Holdings, Inc. He received his undergraduate degree from the University of California, Berkeley and a doctorate degree from Stanford University School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 18.06.2026 | 0 ( -.--% ) | - $ | 31.08.2026 |
Aktive Positionen von Graham Walmsley
| Unternehmen | Position | Beginn |
|---|---|---|
| OLEMA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 01.03.2020 |
Logos Capital Fund LLP
 Logos Capital Fund LLP Investment Trusts/Mutual FundsMiscellaneous Functions as a pooled investment fund | Gründer | 01.08.2019 |
ALX Oncology, Inc.
 ALX Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company which develops therapies for cancers | Direktor/Vorstandsmitglied | 01.02.2020 |
Logos Global Management LP
 Logos Global Management LP Investment ManagersFinance Logos seeks to generate superior risk adjusted returns. The firm intends to deliver capital appreciation for the Public Funds primarily through a mix of long and short investment strategies, including a number of hedging strategies to preserve capital and manage risk exposure. Most of the Public Funds’ assets are expected to be invested on a global basis in publicly traded equity securities in the healthcare and life sciences industries. | Gründer | 01.03.2019 |
Ehemalige bekannte Positionen von Graham Walmsley
| Unternehmen | Position | Ende |
|---|---|---|
| AKERO THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 09.12.2025 |
| ALX ONCOLOGY HOLDINGS INC. | Direktor/Vorstandsmitglied | 01.08.2021 |
Versant Venture Management LLC
 Versant Venture Management LLC Investment ManagersFinance Versant Ventures invests in biotechnology companies located globally. The firm participates in early and later stage capital requirements. | Private Equity Investor | 01.08.2019 |
| CONTINEUM THERAPEUTICS, INC. | Corporate Officer/Principal | 01.12.2018 |
Jecure Therapeutics, Inc.
 Jecure Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis | Corporate Officer/Principal | 01.11.2018 |
Ausbildung von Graham Walmsley
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
80
Beziehungen ersten Grades
13
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 13 |
|---|---|
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Ventures invests in biotechnology companies located globally. The firm participates in early and later stage capital requirements. | Finance |
Stanford University School of Medicine
 Stanford University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Logos Capital Fund LLP
Logos Capital Fund LLP Investment Trusts/Mutual FundsMiscellaneous Functions as a pooled investment fund | Miscellaneous |
Jecure Therapeutics, Inc.
Jecure Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis | Commercial Services |
Akero Therapeutics, Inc.
 Akero Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for patients with metabolic diseases | Health Technology |
Olema Pharmaceuticals, Inc.
 Olema Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for the treatment & prevention of estrogen receptor positive breast cancer | Health Technology |
ALX Oncology, Inc.
ALX Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company which develops therapies for cancers | Health Technology |
Logos Global Management LP
Logos Global Management LP Investment ManagersFinance Logos seeks to generate superior risk adjusted returns. The firm intends to deliver capital appreciation for the Public Funds primarily through a mix of long and short investment strategies, including a number of hedging strategies to preserve capital and manage risk exposure. Most of the Public Funds’ assets are expected to be invested on a global basis in publicly traded equity securities in the healthcare and life sciences industries. | Finance |
Pipeline Therapeutics, Inc.
 Pipeline Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company that develops novel, oral small molecule therapies for neuroscience, inflammation and immunology indications | Health Technology |
ALX Oncology Holdings, Inc.
 ALX Oncology Holdings, Inc. BiotechnologyHealth Technology Operates as clinical stage immuno-oncology company, which develops therapies for cancer | Health Technology |
Lifesci Acquisition II Corp.
 Lifesci Acquisition II Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Science 37 Holdings, Inc.
 Science 37 Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical research company | Commercial Services |
